Summary
Seasoned global clinical development operations leader with experience building and running clinical operations teams across big pharma and biotech. centessa+1
Proven oncology clinical operations expertise, including managing clinical trials, data management, process improvement and CRO/vendor relationships for oncology programs. centessa+1
Contributor to clinical research outputs and conference presentations (e.g., SITC poster acknowledgements and conference abstracts), indicating hands-on involvement with clinical trial programs. replimune+1
Maintains a life outside work that includes significant residential renovation projects and local community ties in Somerville, Massachusetts. bostonglobe+1
Work
Education
Projects
Writing
IGNYTE: An open-label, multicenter, phase 1/2 clinical trial of RP1 + nivolumab (poster)
January 1, 2021Poster presentation of the IGNYTE phase 1/2 trial design, eligibility criteria, endpoints and acknowledgements for contributors including April Dovholuk; presented at SITC 2021.
A phase 1 dose escalation study and signs of anti-metastatic activity of ARQ 197, a selective c-Met inhibitor
January 1, 2007Conference abstract/presentation reporting a phase 1 dose-escalation study of ARQ 197 (selective c-Met inhibitor) with findings on safety, dosing and signs of anti-metastatic activity; April Dovholuk is listed among contributors/authors in the proceedings.